ALLMedicine™ Advanced Prostate Cancer Center

Dec 2nd, 2022 - Androgen deprivation therapy (ADT) is the longstanding treatment for advanced prostate cancer (PC) because androgen receptor (AR) is the key therapeutic vulnerability for this disease. Bipolar androgen therapy (BAT) - the rapid cycling of supraphy...

Dec 1st, 2022 - Abiraterone acetate (AA) is a drug used in advanced prostate cancer. However, known clinical factors with predictive and prognostic value are scarce. This study evaluated cardiovascular (CV) factors and geriatric scales as potential markers of sup...

Dec 1st, 2022 - Epidemiological evidence supports a role for statins in improving survival in advanced prostate cancer, particularly among men receiving androgen-ablative therapies. To study the association between statin use and survival among men with prostate ...

Dec 1st, 2022 - Androgen deprivation therapy has a central role in the treatment of advanced prostate cancer, often causing initial tumour remission before increasing independence from signal transduction mechanisms of the androgen receptor and then eventual dise...

Nov 30th, 2022 - A potential method for focal therapy in locally advanced prostate cancer is focal brachytherapy (F-BT). The purpose of this research was to evaluate midterm F-BT oncologic, functional, and toxicological results in men who had therapy for prostate ...

Dec 15th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|radiotherapy,

Sep 23rd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...

Sep 23rd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...

Sep 7th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|diagnostic imaging,radiotherapy,

Aug 12th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...

Oct 14th, 2022 - PRIMARY OBJECTIVE: I. To evaluate efficacy of erdafitinib in subjects with advanced prostate cancer who have progressed on a second-generation androgen receptor (AR)-targeting agents (SART). SECONDARY OBJECTIVES: I. To evaluate the objective respo...

Oct 14th, 2022 - This study is a multicenter, randomized, open-label, dose finding study of VERU-100 to attain and maintain serum total testosterone levels within castrate range (<50ng/dL) in men with advanced prostate cancer. Stage 1 of the study will assess the ...

Oct 13th, 2022 - Many patients with metastatic prostate cancer who succumb to the disease are initially diagnosed with localized prostate cancer, where treatment has the potential to be curative. For men initially diagnosed with high risk or locally advanced prost...

Oct 13th, 2022 - Prostate cancer ranks second among all malignancies in men and has become a significant threat to men's health. Surgical resection is the main treatment for patients with early and locally advanced prostate cancer. With the progress of technology,...

Oct 5th, 2022 - The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/surveys are being collected in: United States, Can...

Nov 29th, 2022 - Metastasis-directed therapy (MDT) in selected patients with recurrent oligometastatic prostate cancer led to PSA responses in a majority of patients and delayed initiation of hormonal therapy by 18 months, a retrospective study showed. Overall, 77...

Nov 21st, 2022 - The FDA has approved leuprolide acetate injection for use in the palliative treatment of patients with advanced prostate cancer.1,2 A synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone, leuprolide acetate has great...

Nov 18th, 2022 - Treatment developments in advanced prostate cancer are hinging on the benefits of triplet therapy and individualized care, the results of which are also informing treatment sequencing, according to Jason M. Hafron, MD. In an interview during the...

Nov 14th, 2022 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of olaparib (Lynparza) in combination with abiraterone acetate (Zytiga) and prednisone or prednisolone for use in adult patients wit...

Nov 12th, 2022 - All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic impl...